Results 91 to 100 of about 4,593,278 (410)

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients

BMC Gastroenterology, 2023
Background Neoadjuvant therapy favors the prognosis of various cancers, including esophagogastric junction cancer (EGC). However, the impacts of neoadjuvant therapy on the number of dissected lymph nodes (LNs) have not yet been evaluated in EGC.
Qi Wang, Jin-tong Ge, Hua Wu, Sheng Zhong, Qing-quan Wu   +4 more
doaj   +1 more source

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

Current Treatment Options in Oncology, 2021
Recently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach.
E. Zelin, I. Zalaudek, M. Agozzino, C. Dianzani, A. Dri, N. di Meo, R. Giuffrida, G. Marangi, N. Neagu, P. Persichetti, L. Toffoli, C. Conforti   +11 more
semanticscholar   +1 more source

Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single‐center retrospective study in China

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To assess the predictive capability of CT radiomics features for early recurrence (ER) of pancreatic ductal adenocarcinoma (PDAC). Methods Postoperative PDAC patients were retrospectively selected, all of whom had undergone preoperative CT imaging and surgery. Both patients with resectable or borderline‐resectable pancreatic cancer met
Xinze Du, Yongsu Ma, Kexin Wang, Xiejian Zhong, Jianxin Wang, Xiaodong Tian, Xiaoying Wang, Yinmo Yang   +7 more
wiley   +1 more source

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer

Frontiers in Oncology, 2022
BackgroundNeoadjuvant therapy is a standard treatment for patients with large, nonmetastatic breast cancer and may allow breast-conserving surgery after tumor downsizing while decreasing the risk of subsequent relapse.
Jinmei Zhou, Jiangling Wu, Jiangling Wu, Xiaopeng Hao, Ping Li, Huiqiang Zhang, Xuexue Wu, Jiaxin Chen, Jiawei Liu, Jinyi Xiao, Shaohua Zhang, Zefei Jiang, Yanlian Yang, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Tao Wang   +18 more
doaj   +1 more source

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

JAMA Oncology, 2019
Importance The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection. Objective To analyze the outcomes of WW among patients with rectal cancer who had a clinical complete response to neoadjuvant therapy.
J. J. Smith, P. Strombom, O. Chow, Campbell S. Roxburgh, Campbell S. Roxburgh, P. Lynn, A. Eaton, M. Widmar, K. Ganesh, R. Yaeger, A. Cercek, M. Weiser, G. Nash, J. Guillem, Larissa K.F. Temple, Sreedevi Chalasani, J. Fuqua, I. Petkovska, A. Wu, M. Reyngold, E. Vakiani, J. Shia, N. Segal, James D. Smith, C. Crane, M. Gollub, M. Gonen, L. Saltz, J. García-Aguilar, P. Paty   +29 more
semanticscholar   +1 more source

Triple positive breast cancer. A distinct subtype? [PDF]

, 2015
Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression.
A. Cassano, A. Michelotti, C. Botti, C. Natoli, D. Sergi, F. Conti, F. Izzo, I. Sperduti, L. D'Onofrio, L. D. Lauro, L. Mariani, L. Moscetti, L. Pizzuti, M. Barba, M. Maugeri Saccà, M. Mottolese, MARCHETTI, PAOLO, P. Vici, T. Gamucci, V. Rossi   +19 more
core   +1 more source

BAG2 Inhibits Cervical Cancer Progression by Modulating Type I Interferon Signaling through Stabilizing STING

Advanced Science, EarlyView.
Based on IP‐MS analysis, BAG2 is confirmed to be essential for ubiquitination and protein homeostasis regulation of STING in cervical cancer. BAG2 inhibits the ubiquitination and degradation of STING by forming a complex with STUB1, thereby activating the type I IFN signaling pathway and inhibiting the development of cervical cancer.
Shijie Yao, Siming Chen, Anjin Wang, Ziyan Liang, Xuelian Liu, Yang Gao, Hongbing Cai   +6 more
wiley   +1 more source

Survival Outcomes of Patients with Locally Advanced Breast Cancer after Neoadjuvant Systemic Therapy in St. Luke’s Medical Center

Asian Pacific Journal of Cancer Care, 2023
Background: In locally-advanced breast cancers (LABC), the previous primary goal of neoadjuvant systemic therapy was to improve resectability and achieve better margins.
Cristina G. Domingo, Fritz Lorenz E. Ortega, Mark James Arce, Mel Valerie B. Cruz-Ordinario, Agnes E. Gorospe, Carlos Dy   +5 more
doaj   +1 more source

Adjuvant and neoadjuvant therapy for breast cancer.

Japanese Journal of Clinical Oncology, 2020
Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer ...
T. Shien, H. Iwata
semanticscholar   +1 more source